AzTrials
AzTrials

Labor LongHYDRATANCT03607929

HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor

A study testing optimal and variability in people with Labor Long and Nulliparity, run by Puerta de Hierro University Hospital at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Aim. To evaluate the efficacy of optimizing hydration during labor in nulliparous women with respect to reducing the duration of dilation and the second stage of labor, lowering the incidence of Cesarean sections and fever, and also with respect to changes in sodium and osmolarity in blood and urine, and 24 hour… Read more about this study

Who is it for?
Ages 29 to 35 years, women onlyHealthy volunteers can take part
What is being tested?
optimal and variability
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
130 participants
Where
1 siteSpain
Study dates
1 Jun 2018to 31 Dec 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 29 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Are 18 years-of-age or older;
  • With gestation between 37-41+3 weeks
  • Have signed an informed consent form.
  • Exclusion Criteria: The following exclusion criteria will apply:
  • Women who do not have sufficient understanding of the Spanish language or those with whom communication will be difficult
  • Women with a multiple gestation
Show all 14Show fewer
  • Gestation with high maternal or neonatal risk
  • Maternal pathology (metabolic diseases, preeclampsia, eclampsia, etc.)
  • Fetal pathology
  • Precipitated delivery; fetal death.
  • Criteria for leaving the study:
  • Severe maternal complications during the immediate or intermediate postpartum periods that require admittance to the Intensive care Unit
  • Neonatal complications that require admittance to the Neonatology Service for more than 48 hours
  • If, once the study has started, the participant fails to cooperate during follow-up (delivery, during the immediate or intermediate postpartum periods) or decides to discontinue their participation.

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Ana Belen Hernandez Lopez, MSc PhD contact

+34675529071

anabelen.hernandez2@salud.madrid.org

Montserrat Solis Muñoz, MSc PhD RN contact

+341916000 ext. 417457

montserrat.solis@salud.madrid.org

Spain1 site, 1 recruiting
  • Puerta de Hierro Majadahonda University Hospital

    Madrid, 28222

    Montserrat M Solís-Muñoz, Doctor, 670521351, montserrat.solis@salud.madrid.org

    Ana Belén AB Hernández-López, Master, 675529071, kelaynana@gmail.com

    Recruiting

Other trials in Spain

About this study

Official title: Effectiveness "HIDRATACION OPTIMA " During Labor in Reducing Time Dilation and Expulsion, Cesarean, Fever and Dehydration

Aim. To evaluate the efficacy of optimizing hydration during labor in nulliparous women with respect to reducing the duration of dilation and the second stage of labor, lowering the incidence of Cesarean sections and fever, and also with respect to changes in sodium and osmolarity in blood and urine, and 24 hour diuresis.

Background. In the international scientific community there is a lack of consensus regarding the most suitable hydration strategies to be used in the attention of nulliparous women during low risk birth. Insufficient hydration during labor is associated with increased maternal and neonatal morbidity.

Read more

Design. A randomized, controlled clinical trial with allocation concealment and masking during the evaluation of the results.

Methods. A study of nulliparous women whose births and newborn are attended in the Obstetric Service of a University Hospital. The women will be randomized to two groups: the "optimal hydration" group, that will be guaranteed 300 ml/h (intravenous crystalloids and water) with a minimum diuresis of 400 ml/24h; and the "variability in hydration" group, comprised of the administration of intravenous and clear liquid volumes, without any established perfusion rate, based on criteria established by the healthcare professional attending the birth, and without established minimum diuresis. Mother outcomes: duration of labor, Cesarean section, fever, dehydration. Newborn outcomes: distress, hypoglycemia, hyponatremia, jaundice, weight loss in 48h, breastfeeding difficulties. Analysis will be per-protocol. Statistical significance will be set at p<0.05 Discussion. The findings obtained in this study will provide new evidence for considering the benefits of providing women with suitable optimized hydration during labor. Diminishing the clinical practice variability related to hydration strategies applied to nulliparous women attended during labor through the use of a decision-making algorithm to administer optimal hydration, would imply improved health and safety for mothers and their newborn together with reduced maternal and neonatal morbidity.

Funding granted in 2015 by the Spanish Health Research Fund (PI 15/00897, Ministry of Health).

Keywords: hydration; dehydration; adverse events; labor; Cesarean section, fever.

Read the detailed description

PRIMARY AIM:

To evaluate the efficacy of "optimal hydration" during labor in nulliparous pregnant women attended for spontaneous or induced deliveries with respect to the reduction in dilation times, second stage of labor and total labor time.

METHODOLOGY A randomized controlled clinical trial, with concealed allocation. The study is being carried out in a large university hospital belonging to the Spanish National Health System. The trial is being carried out in the Obstetrics Service in Hospital Universitario Puerta de Hierro Majadahonda, Madrid. All the study participants will be nulliparous women (women who have not given birth by the vaginal route), and their neonates, who are attended during either spontaneous labor (2-3 regular uterine contractions in 10 minutes, cervical effacement greater than 50% and 3-4 cm spontaneous dilatation) or induced labor (when labor is induced artificially). The sample size was estimated on the basis of cohorts previously studied by the same team of investigators in the same hospital which observed that women who had received liquid volumes of less than 300 ml/h during labor took a mean (SD) of 754 (251) minutes to complete the birth, whereas women who received a volume equal to or greater than 300 ml/h took a mean (SD) of 592 (287) minutes. Assuming a 95% confidence interval, in a bilateral contrast, with a statistical power of 90%, a population of 59 is required for each group. In addition, a 10% increase is taken into account for those lost to follow-up. Therefore, the final sample size is 130, with 65 women in each group.

Intervention group protocol: "optimal hydration" Women in this group will be attended by the 13 investigation team midwives who have agreed to collaborate with the study's clinical team. Attention will include: (A) administration of a volume of liquids equal to 300 ml/h during labor which is defined as from the moment of admittance to the delivery room until the birth of the child; (B) more than 80% of the volume will be perfused intravenously using a physiological saline solution; (C) the women will be encouraged to drink clear liquids from the moment of admittance to the delivery room until reaching 10 cm dilation, such liquids will only be bottled mineral water (80%) and isotonic drinks (20%); (D) the perfusion rate will be increased if the woman has diuresis lower than 400 ml in 24h or presents temperature equal to or greater than 37.8ºC.

Control group protocol: "variability in hydration" Women in this group will be attended by the 16 delivery room midwives who do not belong to the investigation team. The women will be hydrated in accordance with the midwives' experience, training and clinical criteria, either independently or jointly with the attending clinicians (obstetricians, gynecologists and anesthetists). The principal lines of attention will be: (A) administration of undetermined volumes of liquids during labor which is defined as from the moment of admittance to the delivery room until the birth of the child; (B) the volume will be perfused intravenously using physiological saline solution, Ringer's, 5% glucose, 10% glucose or voluven; (C) the women will be allowed to drink clear liquids at their own pace and to their liking from the moment of admittance to the delivery room until reaching 10 cm dilation, such liquids can be water and isotonic drinks; (D) changes in perfusion rate and diuresis or increases in temperature (higher then 37.7ºC) will not be evaluated.

Study procedures The midwife in the Obstetric Emergency department will verify whether women attending the service comply with the criteria for inclusion in the study but do not present any exclusion criteria. In such cases, the midwife will give the woman verbal and written information about the study. If the woman is willing to participate, she will have to return a signed Informed Consent form to the midwife. The woman will at this moment be assigned the next consecutive number for inclusion in the study. The midwife will open the corresponding envelope containing the information regarding the group to which the woman has been assigned. In the case of assignment to the "controled hydration" group, the midwife responsible for her attention will be one of the 13 in the investigating team. If the woman is assigned to the "uncontroled in hydration" group, the midwife responsible for her attention will be one of the 16 who do not belong to the investigating team.

Study measures

Maternal variables:

  • Main Outcomes: duration of dilation, duration of second stage of labor, and total duration from onset of labor until the birth.
  • Secondary Outcomes: times on oxytocin, with ruptured membrane and epidural anesthesia, incidence of Cesarean section, incidence of intrapartum fever (temperature equal to or higher than 38ºC) and postpartum fever, dehydration (diuresis lower than 400 ml in 24 h, osmolarity concentration in urine/blood, sodium in urine/blood), headaches, nausea, vomiting, confusional state, hyperglycemia (blood sugar higher than 120 mg/dl), difficulty establishing breastfeeding, badly controlled thirst, badly controlled pain.
  • Sociodemographic variables: age, nationality, educational level.
  • Clinical variables on admittance, intrapartum, immediate postpartum (first 2 hours) and intermediate postpartum period (24 and 48 hours).

Neonate variables:

  • Neonate outcomes: distress, seizures, nausea, vomiting, tachypnea, hypoglycemia (glycemia lower than 40 ml/dl), hyponatremia (sodium in umbilical cord blood <130 mEq/L), fever (temperature equal to or higher than 38ºC), jaundice (requiring phototherapy), more than 7% weight loss in 48 h, difficulty initiating breast feeding.
  • Variables related to the newborn child (from birth, at 24 and 48 h): ions (sodium, potassium and glucose) in umbilical cord blood, gender, weight (at birth, at 24 and 48 h), distress, temperature, desire to suckle, colostrum, initiation of breastfeeding, type of breastfeeding, jaundice and capillary bilirubin levels (24 and 48 h).

Data collection Information will be collected from: clinical histories, partogram, observation, physical examination, fetal monitoring, scales (adult and newborn), analytical values, vital signs, visual analogue scale for pain (from 0 to 10), sensation of nausea (from 0 to 5), sensation of thirst (from 0 to 10), Armstrong scale (dehydration evaluation), Bilitest (capillary bilirubin levels), Silverman test (respiratory distress at birth). Maternal laboratory values: antenatal and in the immediate postpartum. Requests for blood and urine samples and their extraction, together with all other analyses, will be carried out by the Emergency Obstetric Service midwife according to normal clinical practice. Neonate laboratory values: at the time of birth. Requests for analyses will be made by the midwife during the dilation phase. Taking advantage of the moment when other samples are taken according to normal clinical practice (umbilical cord pH and blood group), sample extractions will be carried out by the midwife or obstetrician attending the delivery. The midwife will be responsible for weighing the newborn in the delivery room and in the Obstetric Service ward. The variables corresponding to the immediate postpartum (24-48 h) will be recorded by ward nurses who will be blinded to the group assignments.

Data analysis Analyses will be carries by assigned treatment and by intention to treat. Mean differences will be presented for qualitative values, and relative risks, reductions of relative and absolute risk, and the number required to treat for qualitative variables. All variables will be shown with their 95% confidence interval. Statistical significance will be set at p<0.05.

Being tested
optimal, variability
Keywords
ARE, deshydration, adverse events, cesarean, fever
Medical subject headings
Fetal Membranes, Premature Rupture, Pregnancy, Prolonged, Fever

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • optimalProcedure or surgery

    Also called controlled

    Physiological Saline Solution

  • variabilityProcedure or surgery

    Also called uncontrolled

    Other solutions

Study groups in NCT03607929
Study groupRoleWhat they receive
optimal and hydrationExperimentalPhysiological Saline Solution 300 ml/h AND drink freely mineral water during labor
Receives: Procedure: optimal
variability and hydrationActive comparatorOther Solutions >o < 300 ml/h AND uncontrolled drink during labor
Receives: Procedure: variability

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. duration of labor

    total duration from onset of labor until the birth.

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jul 2018
  2. Study start1 Jun 2018
  3. Primary completion31 Dec 2020 (estimated)
  4. Study completion31 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
INTERVENTION GROUP " OPTIMAL HYDRATION" LABOR: they will be initiated the administration of crystalloid solutions in continuous perfusion at a rate of 200ml/h, until delivery, alternating each of them: (1)Physiological Serum (2)Physiological Serum (3)Ringer Lactate. The oral intake of mineral water will be promoted, at a rate of 100ml/h. To avoid bias, the mineral water will be administered by the research team. IMMEDIATE PUERPERIUM: Women who have had a low-risk delivery will drink mineral water at a rate of 100ml / h during the two hours of the immediate puerperium. Suspending Hydration i.v. CONTROL GROUP " VARIABILITY IN HYDRATION" The women will be hydrated in accordance with the midwives' experience, training and clinical criteria, either independently or jointly with the attending clinicians (obstetricians, gynecologists and anesthetists).
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03607929
Sponsor's protocol ID
PuertadeHierro
Other IDs
PI15/00897
Acronym
HYDRATA
Status last verified
Sep 2020
First submitted
23 Jul 2018
Last updated
23 Sep 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing optimal and variability in people with Labor Long and Nulliparity, run by Puerta de Hierro University Hospital at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ana Belen Hernandez Lopez, MSc PhD (+34675529071, anabelen.hernandez2@salud.madrid.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

duration of labor (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in